

Patrick S Parfrey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2191559/publications.pdf>

Version: 2024-02-01

158
papers

15,660
citations

34016

52
h-index

16605

123
g-index

162
all docs

162
docs citations

162
times ranked

11432
citing authors

#	ARTICLE	IF	CITATIONS
1	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2009, 361, 2019-2032.	13.9	2,110
2	Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. <i>Kidney International</i> , 1995, 47, 186-192.	2.6	1,094
3	Contrast Material-Induced Renal Failure in Patients with Diabetes Mellitus, Renal Insufficiency, or Both. <i>New England Journal of Medicine</i> , 1989, 320, 143-149.	13.9	957
4	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	13.9	805
5	The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. <i>American Journal of Kidney Diseases</i> , 1996, 28, 53-61.	2.1	699
6	Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors. <i>Kidney International</i> , 1995, 47, 884-890.	2.6	605
7	The Cardinal Manifestations of Bardet-Biedl Syndrome, a Form of Laurence-Moon-Biedl Syndrome. <i>New England Journal of Medicine</i> , 1989, 321, 1002-1009.	13.9	527
8	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2010, 363, 1146-1155.	13.9	433
9	Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Is a Fully Penetrant, Lethal Arrhythmic Disorder Caused by a Missense Mutation in the TMEM43 Gene. <i>American Journal of Human Genetics</i> , 2008, 82, 809-821.	2.6	431
10	Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. <i>Kidney International</i> , 2000, 58, 1325-1335.	2.6	357
11	Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2180-2189.	3.0	343
12	The Diagnosis and Prognosis of Autosomal Dominant Polycystic Kidney Disease. <i>New England Journal of Medicine</i> , 1990, 323, 1085-1090.	13.9	331
13	Contrast Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 177-182.	3.0	319
14	Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with Bardet-Biedl syndrome. <i>Nature Genetics</i> , 2000, 26, 67-70.	9.4	311
15	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. <i>Circulation</i> , 2015, 132, 27-39.	1.6	259
16	Mutations in MKKS cause Bardet-Biedl syndrome. <i>Nature Genetics</i> , 2000, 26, 15-16.	9.4	256
17	Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: A 22-year prospective, population-based, cohort study. <i>American Journal of Medical Genetics, Part A</i> , 2005, 132A, 352-360.	0.7	249
18	Congestive Heart Failure in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1084-1090.	3.0	241

#	ARTICLE	IF	CITATIONS
19	Left Ventricular Hypertrophy in the Renal Patient. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1079-1084.	3.0	235
20	Serial Change in Echocardiographic Parameters and Cardiac Failure in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2000, 11, 912-916.	3.0	208
21	Electrocardiographic Left Ventricular Hypertrophy in Renal Transplant Recipients: Prognostic Value and Impact of Blood Pressure and Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 462-468.	3.0	182
22	The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). <i>Journal of the American College of Cardiology</i> , 2005, 45, 400-408.	1.2	164
23	Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1466-1475.	3.0	163
24	The Spectrum of Renal Disease in Laurenceâ€œMoonâ€œBiedl Syndrome. <i>New England Journal of Medicine</i> , 1988, 319, 615-618.	13.9	156
25	Bilineal Disease and Trans-Heterozygotes in Autosomal Dominant Polycystic Kidney Disease. <i>American Journal of Human Genetics</i> , 2001, 68, 355-363.	2.6	146
26	Somatic PKD2 Mutations in Individual Kidney and Liver Cysts Support a â€œTwo-Hitâ€œ Model of Cystogenesis in Type 2 Autosomal Dominant Polycystic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1524-1529.	3.0	145
27	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 898-905.	2.2	144
28	Left Ventricular Hypertrophy in New Hemodialysis Patients without Symptomatic Cardiac Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 805-813.	2.2	125
29	The importance of renal impairment in the natural history of bardet-biedl syndrome. <i>American Journal of Kidney Diseases</i> , 1996, 27, 776-783.	2.1	120
30	Sudden cardiac death in chronic kidney disease: epidemiology and prevention. <i>Nature Reviews Nephrology</i> , 2011, 7, 145-154.	4.1	118
31	A Fifth Locus for Bardet-Biedl Syndrome Maps to Chromosome 2q31. <i>American Journal of Human Genetics</i> , 1999, 64, 900-904.	2.6	117
32	Mutations of PKD1 in ADPKD2 cysts suggest a pathogenic effect of trans-heterozygous mutations. <i>Nature Genetics</i> , 2000, 25, 143-144.	9.4	116
33	Rationaleâ€œTrial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. <i>American Heart Journal</i> , 2005, 149, 408-413.	1.2	115
34	Autosomal dominant polycystic kidney disease: New information for genetic counselling. <i>American Journal of Medical Genetics Part A</i> , 1992, 43, 548-553.	2.4	107
35	The Effect of Cinacalcet on Calcific Uremic Arteriopathy Events in Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 800-807.	2.2	107
36	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EVALUATION Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001363.	1.6	105

#	ARTICLE	IF	CITATIONS
37	Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 755-762.	2.2	102
38	The Clinical Epidemiology of Contrast-Induced Nephropathy. <i>CardioVascular and Interventional Radiology</i> , 2005, 28, S3-S11.	0.9	95
39	Stroke in Patients With Type 2 Diabetes Mellitus, Chronic Kidney Disease, and Anemia Treated With Darbepoetin Alfa. <i>Circulation</i> , 2011, 124, 2903-2908.	1.6	89
40	Meta-analysis of 16 studies of the association of alcohol with colorectal cancer. <i>International Journal of Cancer</i> , 2020, 146, 861-873.	2.3	89
41	Dietary nitroso compounds and risk of colorectal cancer: a case-control study in Newfoundland and Labrador and Ontario, Canada. <i>British Journal of Nutrition</i> , 2014, 111, 1109-1117.	1.2	82
42	Genetic and Mutational Analyses of a Large Multiethnic Bardet-Biedl Cohort Reveal a Minor Involvement of BBS6 and Delineate the Critical Intervals of Other Loci. <i>American Journal of Human Genetics</i> , 2001, 68, 606-616.	2.6	80
43	Factors Governing Cardiovascular Risk in the Patient with a Failing Renal Transplant. <i>Peritoneal Dialysis International</i> , 2001, 21, 275-279.	1.1	75
44	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 791-799.	2.2	75
45	Promoter methylation of Wnt antagonists <i>DKK1</i> and <i>SFRP1</i> is associated with opposing tumor subtypes in two large populations of colorectal cancer patients. <i>Carcinogenesis</i> , 2011, 32, 741-747.	1.3	74
46	Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. <i>Kidney International</i> , 1994, 46, 1118-1123.	2.6	69
47	Mechanisms of the cardiorenal syndromes. <i>Nature Reviews Nephrology</i> , 2009, 5, 641-649.	4.1	69
48	Incident Renal Events and Risk Factors in Autosomal Dominant Polycystic Kidney Disease: A Population and Family-Based Cohort Followed for 22 Years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 710-717.	2.2	67
49	Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 726-733.	2.2	64
50	Genetic Heterogeneity of Bardet-Biedl Syndrome in a Distinct Canadian Population: Evidence for a Fifth Locus. <i>Genomics</i> , 1999, 55, 2-9.	1.3	63
51	The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4834-4844.	1.8	63
52	Darbepoetin Alfa Impact on Health Status in Diabetes Patients with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 845-855.	2.2	53
53	Canadian Bardet-Biedl syndrome family reduces the critical region of BBS3 (3p) and presents with a variable phenotype. , 1998, 78, 461-467.		49
54	High Frequency of Hereditary Colorectal Cancer in Newfoundland Likely Involves Novel Susceptibility Genes. <i>Clinical Cancer Research</i> , 2005, 11, 6853-6861.	3.2	46

#	ARTICLE	IF	CITATIONS
55	A Founder Effect in the Newfoundland Population Reduces the Bardet-Biedl Syndrome I (BBS1) Interval to 1 cM. <i>American Journal of Human Genetics</i> , 1999, 65, 1680-1687.	2.6	45
56	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2872-2879.	0.4	45
57	Genetic architectures of proximal and distal colorectal cancer are partly distinct. <i>Gut</i> , 2021, 70, 1325-1334.	6.1	44
58	Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. <i>Kidney International</i> , 2018, 93, 1475-1482.	2.6	41
59	Nongenetic Determinants of Risk for Early-Onset Colorectal Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab029.	1.4	39
60	Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in <i>TMEM43</i> Following Implantable Cardioverter Defibrillator Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	37
61	Specific Variants in the MLH1 Gene Region May Drive DNA Methylation, Loss of Protein Expression, and MSI-H Colorectal Cancer. <i>PLoS ONE</i> , 2010, 5, e13314.	1.1	35
62	Clinical and genetic epidemiology of inherited renal disease in Newfoundland. <i>Kidney International</i> , 2002, 61, 1925-1934.	2.6	34
63	The phenotypic expression of three MSH2 mutations in large Newfoundland families with Lynch syndrome. <i>Familial Cancer</i> , 2007, 6, 1-12.	0.9	34
64	Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1669-1675.	2.2	33
65	The long-term survival characteristics of a cohort of colorectal cancer patients and baseline variables associated with survival outcomes with or without time-varying effects. <i>BMC Medicine</i> , 2019, 17, 150.	2.3	32
66	MTHFR Glu429Ala and ERCC5 His46His Polymorphisms Are Associated with Prognosis in Colorectal Cancer Patients: Analysis of Two Independent Cohorts from Newfoundland. <i>PLoS ONE</i> , 2013, 8, e61469.	1.1	30
67	Community engagement with genetics: public perceptions and expectations about genetics research. <i>Health Expectations</i> , 2015, 18, 1413-1425.	1.1	30
68	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2016, 68, 873-881.	2.1	28
69	Intake of Dietary Fruit, Vegetables, and Fiber and Risk of Colorectal Cancer According to Molecular Subtypes: A Pooled Analysis of 9 Studies. <i>Cancer Research</i> , 2020, 80, 4578-4590.	0.4	26
70	Interaction between alcohol drinking and obesity in relation to colorectal cancer risk: a case-control study in Newfoundland and Labrador, Canada. <i>BMC Public Health</i> , 2012, 12, 94.	1.2	25
71	Two phosphate targets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 965-973.	2.2	25
72	Coronary Artery Disease Is a Predictor of Progression to Dialysis in Patients With Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Anemia: An Analysis of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	24

#	ARTICLE	IF	CITATIONS
73	Inflammatory diet and risk for colorectal cancer: A population-based case-control study in Newfoundland, Canada. <i>Nutrition</i> , 2017, 42, 69-74.	1.1	24
74	Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 177-181.	1.0	22
75	Genetic structure of the Newfoundland and Labrador population: founder effects modulate variability. <i>European Journal of Human Genetics</i> , 2016, 24, 1063-1070.	1.4	22
76	Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) Tj ETQqO 0.0 rgBT /Overlock 10 Diseases, 2013, 61, 238-246.	2.1	21
77	The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial. <i>Contemporary Clinical Trials</i> , 2016, 48, 119-124.	0.8	21
78	Pathogenesis of Cardiac Disease in Dialysis Patients. <i>Seminars in Dialysis</i> , 1999, 12, 62-68.	0.7	20
79	Target Hemoglobin Level for EPO Therapy in CKD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 171-173.	2.1	20
80	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 539-546.	2.2	20
81	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2039-2048.	0.4	20
82	Left Ventricular Hypertrophy in Dialysis Patients. <i>Seminars in Dialysis</i> , 1992, 5, 34-41.	0.7	19
83	Analyzing Health-Related Quality of Life in the EVOLVE Trial. <i>Medical Decision Making</i> , 2016, 36, 965-972.	1.2	19
84	Translation of research discoveries to clinical care in arrhythmogenic right ventricular cardiomyopathy in Newfoundland and Labrador: Lessons for health policy in genetic disease. <i>Genetics in Medicine</i> , 2009, 11, 859-865.	1.1	18
85	Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population. <i>British Journal of Cancer</i> , 2017, 117, 898-906.	2.9	18
86	Hypothesis and data-driven dietary patterns and colorectal Cancer survival: findings from Newfoundland and Labrador colorectal Cancer cohort. <i>Nutrition Journal</i> , 2018, 17, 55.	1.5	18
87	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	2.1	18
88	Antibiotic utilisation in community practices: guideline concurrence and prescription necessity. <i>Pharmacoepidemiology and Drug Safety</i> , 2005, 14, 319-326.	0.9	17
89	Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial. <i>Pharmaceutical Statistics</i> , 2015, 14, 242-251.	0.7	17
90	A genome wide association study on Newfoundland colorectal cancer patients's™ survival outcomes. <i>Biomarker Research</i> , 2015, 3, 6.	2.8	17

#	ARTICLE	IF	CITATIONS
91	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. <i>Value in Health</i> , 2015, 18, 1079-1087.	0.1	16
92	Mitochondrial DNA polymorphisms, its copy number change and outcome in colorectal cancer. <i>BMC Research Notes</i> , 2015, 8, 272.	0.6	16
93	Exercise and arrhythmic risk in TMEM43 p.S358L arrhythmogenic right ventricular cardiomyopathy. <i>Heart Rhythm</i> , 2020, 17, 1159-1166.	0.3	16
94	Clinical research of kidney diseases II: problems of study design. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2785-2794.	0.4	15
95	Risk Stratification for Early-Onset Colorectal Cancer Using a Combination of Genetic and Environmental Risk Scores: An International Multi-Center Study. <i>Journal of the National Cancer Institute</i> , 2022, , .	3.0	15
96	Therapy Insight: management of cardiovascular disease in the renal transplant recipient. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 514-526.	2.0	14
97	Autosomal recessive Bardet-Biedl syndrome: first-degree relatives have no predisposition to metabolic and renal disorders. <i>Kidney International</i> , 2009, 76, 215-223.	2.6	14
98	Germline <i>INDEL</i> s and <i>CNV</i> s in a cohort of colorectal cancer patients: their characteristics, associations with relapse-free survival time, and potential time-varying effects on the risk of relapse. <i>Cancer Medicine</i> , 2017, 6, 1220-1232.	1.3	14
99	Community pharmacist outreach program directed at physicians treating congestive heart failure. <i>American Journal of Health-System Pharmacy</i> , 2000, 57, 747-752.	0.5	13
100	Autosomal-recessive polycystic kidney disease. <i>Kidney International</i> , 2005, 67, 1638-1648.	2.6	13
101	Quality of Life in CKD Patients Treated With Erythropoiesis-Stimulating Agents. <i>American Journal of Kidney Diseases</i> , 2010, 55, 423-425.	2.1	13
102	A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 133.	1.1	13
103	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2008, 473, 1-17.	0.4	10
104	Impact of colonoscopic screening in Familial Colorectal Cancer Type X. <i>Molecular Genetics & Genomic Medicine</i> , 2018, 6, 1021-1030.	0.6	10
105	What do we really know about the appropriateness of radiation emitting imaging for low back pain in primary and emergency care? A systematic review and meta-analysis of medical record reviews. <i>PLoS ONE</i> , 2019, 14, e0225414.	1.1	10
106	Are general practitioners referring patients with low back pain for CTs appropriately according to the guidelines: a retrospective review of 3609 medical records in Newfoundland using routinely collected data. <i>BMC Family Practice</i> , 2020, 21, 236.	2.9	10
107	Penetrance of HNPCC-related cancers in a retrolective cohort of 12 large Newfoundland families carrying a MSH2 founder mutation: an evaluation using modified segregation models. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 16.	0.6	9
108	Cardiac Biomarkers and Health-Related Quality of Life in New Hemodialysis Patients without Symptomatic Cardiac Disease. <i>Canadian Journal of Kidney Health and Disease</i> , 2014, 1, 16.	0.6	9

#	ARTICLE	IF	CITATIONS
109	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021, 235, 1-11.	1.2	9
110	A comprehensive analysis of SNPs and CNVs identifies novel markers associated with disease outcomes in colorectal cancer. <i>Molecular Oncology</i> , 2021, 15, 3329-3347.	2.1	9
111	In the Literature: On Clinical Performance Measures and Outcomes Among Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2007, 49, 352-355.	2.1	8
112	Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. <i>American Journal of Nephrology</i> , 2017, 46, 488-497.	1.4	8
113	Association of rs2282679 A>C polymorphism in vitamin D binding protein gene with colorectal cancer risk and survival: effect modification by dietary vitamin D intake. <i>BMC Cancer</i> , 2018, 18, 155.	1.1	8
114	THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Introduction. <i>Seminars in Dialysis</i> , 2003, 16, 83-84.	0.7	7
115	Promoter methylation of ITF2, but not APC, is associated with microsatellite instability in two populations of colorectal cancer patients. <i>BMC Cancer</i> , 2016, 16, 113.	1.1	7
116	Sustainability of an Enhanced Recovery After Surgery initiative for elective colorectal resections in a community hospital. <i>Canadian Journal of Surgery</i> , 2020, 63, E292-E298.	0.5	7
117	Examining the Polymorphisms in the Hypoxia Pathway Genes in Relation to Outcome in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e113513.	1.1	7
118	No associations of a set of SNPs in the Vascular Endothelial Growth Factor (VEGF) and Matrix Metalloproteinase (MMP) genes with survival of colorectal cancer patients. <i>Cancer Medicine</i> , 2016, 5, 2221-2231.	1.3	6
119	Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0198873.	1.1	6
120	Bias in Clinical Research. <i>Methods in Molecular Biology</i> , 2021, 2249, 17-34.	0.4	6
121	XRCC3 Thr241Met and TYMS variable number tandem repeat polymorphisms are associated with time-to-metastasis in colorectal cancer. <i>PLoS ONE</i> , 2018, 13, e0192316.	1.1	6
122	Autosomal Dominant Polycystic Kidney Disease and End Stage Renal Disease. <i>Seminars in Dialysis</i> , 1991, 4, 26-32.	0.7	5
123	A Survival Association Study of 102 Polymorphisms Previously Associated with Survival Outcomes in Colorectal Cancer. <i>BioMed Research International</i> , 2015, 2015, 1-9.	0.9	5
124	Associations of single nucleotide polymorphisms with mucinous colorectal cancer: genome-wide common variant and gene-based rare variant analyses. <i>Biomarker Research</i> , 2018, 6, 17.	2.8	5
125	Joint nested frailty models for clustered recurrent and terminal events: An application to colonoscopy screening visits and colorectal cancer risks in Lynch Syndrome families. <i>Statistical Methods in Medical Research</i> , 2020, 29, 1466-1479.	0.7	5
126	On Peginesatide and Anemia Treatment in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 62, 659-661.	2.1	4

#	ARTICLE	IF	CITATIONS
127	Prediagnostic consumption of vitamin D, calcium and dairy products and colorectal cancer survival: results from the Newfoundland Colorectal Cancer Registry Cohort Study. <i>British Journal of Nutrition</i> , 2021, , 1-10.	1.2	4
128	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2015, 1281, 3-18.	0.4	4
129	Risk Factors for Cardiac Dysfunction in Dialysis Patients: Implications for Patient Care. <i>Seminars in Dialysis</i> , 1997, 10, 137-141.	0.7	3
130	Linkage disequilibrium mapping in the Newfoundland population: a re-evaluation of the refinement of the Bardet?Biedl syndrome 1 critical interval. <i>Human Genetics</i> , 2005, 116, 62-71.	1.8	3
131	Erythropoietin?stimulating Agents in Chronic Kidney Disease: A Response to Hyporesponsiveness. <i>Seminars in Dialysis</i> , 2011, 24, 495-497.	0.7	3
132	Why does the treatment of anaemia not improve cardiac outcomes in CKD?. <i>Nature Reviews Nephrology</i> , 2013, 9, 59-61.	4.1	2
133	Cardiovascular Disease and Chronic Kidney Disease. , 2015, , 181-198.		2
134	Randomized Controlled Trials 6: On Contamination and Estimating the Actual Treatment Effect. <i>Methods in Molecular Biology</i> , 2015, 1281, 249-259.	0.4	2
135	The effect of laboratory requisition modification, audit and feedback with academic detailing or both on utilization of blood urea testing in family practice in Newfoundland, Canada. <i>Clinical Biochemistry</i> , 2020, 83, 21-27.	0.8	2
136	Anemia as a Risk Factor for Cardiac Disease in Dialysis Patients. <i>Seminars in Dialysis</i> , 1999, 12, 84-86.	0.7	1
137	Editorial Perspective. Should Hemoglobin Targets for Anemic Patients with Chronic Kidney Disease Be Changed. <i>American Journal of Nephrology</i> , 2010, 31, 565-566.	1.4	1
138	Development and preliminary testing of the psychosocial adjustment to hereditary diseases scale. <i>BMC Psychology</i> , 2013, 1, 7.	0.9	1
139	Family physician referral rates for lumbar spine computed tomography in Newfoundland and Labrador: a cross-sectional analysis using routinely collected data. <i>CMAJ Open</i> , 2020, 8, E56-E59.	1.1	1
140	Changing Health-Related Behaviors 2: On Improving the Value of Health Spending. <i>Methods in Molecular Biology</i> , 2021, 2249, 553-569.	0.4	1
141	Changing Health-Related Behaviors 4: Realizing Impact of Health Research Through Knowledge Translation. <i>Methods in Molecular Biology</i> , 2021, 2249, 597-612.	0.4	1
142	Randomized Controlled Trials 1: Design. <i>Methods in Molecular Biology</i> , 2021, 2249, 193-211.	0.4	1
143	Randomized Controlled Trials 4: Planning, Analysis, and Interpretation of Quality-of-Life Studies. <i>Methods in Molecular Biology</i> , 2021, 2249, 247-259.	0.4	1
144	Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. <i>Kidney International Reports</i> , 2021, 6, 1130-1140.	0.4	1

#	ARTICLE	IF	CITATIONS
145	On Framing the Research Question and Choosing the Appropriate Research Design. <i>Methods in Molecular Biology</i> , 2021, 2249, 1-16.	0.4	1
146	Longitudinal Studies 2: Modeling Data Using Multivariate Analysis. <i>Methods in Molecular Biology</i> , 2021, 2249, 103-124.	0.4	1
147	An evaluation of acute care restructuring in Newfoundland and Labrador: conclusions. <i>Journal of Health Services Research and Policy</i> , 2005, 10, 71-73.	0.8	0
148	Evocalcet in the management of secondary hyperparathyroidism in dialysis patients. <i>Kidney International</i> , 2018, 94, 661-662.	2.6	0
149	Longitudinal Studies 3: Data Modeling Using Standard Regression Models and Extensions. <i>Methods in Molecular Biology</i> , 2021, 2249, 125-165.	0.4	0
150	Randomized Controlled Trials 7: On Contamination and Estimating the Actual Treatment Effect. <i>Methods in Molecular Biology</i> , 2021, 2249, 307-318.	0.4	0
151	Randomized Controlled Trials 2: Analysis. <i>Methods in Molecular Biology</i> , 2021, 2249, 213-227.	0.4	0
152	Variation and appropriateness of antipsychotic use in long-term care facilities across Newfoundland and Labrador. <i>Canadian Pharmacists Journal</i> , 2021, 154, 205-212.	0.4	0
153	Bias in Clinical Studies of Genetic Diseases. <i>Methods in Molecular Biology</i> , 2008, 473, 171-186.	0.4	0
154	Title is missing!. , 2019, 14, e0225414.		0
155	Title is missing!. , 2019, 14, e0225414.		0
156	Title is missing!. , 2019, 14, e0225414.		0
157	Title is missing!. , 2019, 14, e0225414.		0
158	Radiocontrast Nephropathy. , 0, , 110-121.		0